Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 12;11(12):3367.
doi: 10.3390/jcm11123367.

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Roberto Russo  1   2 , Niccolò Capurro  1   2 , Emanuele Cozzani  1   2 , Aurora Parodi  1   2
Affiliations
Review

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Roberto Russo et al. J Clin Med. .

Abstract

Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with BP. Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated patients in 9 papers.

Keywords: autoimmune blistering diseases; bullous pemphigoid; dupilumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cozzani E., Marzano A.V., Caproni M., Feliciani C., Calzavara-Pinton P., Cutaneous Immunology Group of SIDeMaST Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. G. Ital. Dermatol. Venereol. Organo Uff. Soc. Ital. Dermatol. Sifilogr. 2018;153:305–315. doi: 10.23736/S0392-0488.18.06006-6. - DOI - PubMed
    1. Russo R., Cozzani E., Gasparini G., Parodi A. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol. Ther. 2020;33:e13190. doi: 10.1111/dth.13190. - DOI - PMC - PubMed
    1. Kaye A., Gordon S.C., Deverapalli S.C., Her M.J., Rosmarin D. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol. 2018;154:1225–1226. doi: 10.1001/jamadermatol.2018.2526. - DOI - PubMed
    1. Seidman J.S., Eichenfield D.Z., Orme C.M. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol. Online J. 2019;25:12. doi: 10.5070/D32511046147. - DOI - PubMed
    1. Saleh M., Reedy M., Torok H., Weaver J. Successful treatment of bullous pemphigoid with dupilumab: A case and brief review of the literature. Dermatol. Online J. 2021;27:7. doi: 10.5070/D3274053155. - DOI - PubMed